CapitalBio officially joins Roche NimbleGen CSP Program

Roche NimbleGen (SWX:RO) (SWX:ROG) (Pink Sheets: RHHBY) announced today that Beijing-based genomic services provider CapitalBio has officially joined the Roche NimbleGen Certified Service Provider (CSP) Program. CapitalBio has been certified to process customer samples for NimbleGen Gene Expression, Comparative Genomic Hybridization/Copy Number Variation (CGH/CNV), and DNA Methylation services in their lab in Beijing, China and is the first NimbleGen CSP in Asia to implement the MS 200 Microarray Scanner into their array workflow for high-resolution scanning CapitalBio brings six years experience of premier genetic research services to the Chinese scientific community, which was instrumental in their certification as a service provider.

“We will now be able to expand our service to customers through access of the complete NimbleGen Single-Color (Gene Expression) or Dual-Color (CGH/CNV & DNA Methylation) workflow. We are pleased to have passed the rigorous certification procedures and experimental standards to become part of the Roche NimbleGen CSP Program”

“The launch of the Roche NimbleGen CSP Program at CapitalBio represents a major step forward in our efforts to bring advanced DNA analysis to China” said Junquan XU, Vice President of Operations at CapitalBio. “We will now be able to expand our service to customers through access of the complete NimbleGen Single-Color (Gene Expression) or Dual-Color (CGH/CNV & DNA Methylation) workflow. We are pleased to have passed the rigorous certification procedures and experimental standards to become part of the Roche NimbleGen CSP Program”.

“Roche NimbleGen is extremely excited to welcome CapitalBio Corporation as our first certified service provider in Asia for the Gene Expression, CGH/CNV, and DNA Methylation array applications. CapitalBio Corporation’s reputation of excellence within the Chinese genomics community coupled with their adoption of the NimbleGen products effectively positions us for tremendous future growth in this rapidly developing market" said Andreas Görtz, Vice President of Marketing for Roche NimbleGen, Inc.

Source:

Roche NimbleGen

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Gene mutations in the ClC-2 chloride channel cause high blood pressure, kidney damage